Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered by orally for the treatment of patients with nonalcoholic steatohepatitis (NASH) and other diseases with significant unmet medical need, today announces that the United States Patent and Trademark Office (USPTO) has issued a patent (US Patent No. 11,504,380) which protects the use of lanifibranor for the treatment of cirrhotic patients whose disease is at risk of progressing from the compensated stage to the decompensated stage. This patent will expire on November 8, 2039.